Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 709.50K | 977.80K | 1.25M | 774.10K | 553.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.81M | 2.98M | 3.15M | 2.57M | 2.26M |
| Operating Income | -2.81M | -2.98M | -3.15M | -2.57M | -2.26M |
| Income Before Tax | -3.55M | -4.38M | -5.20M | -4.25M | -3.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.55 | -4.38 | -5.20 | -4.25 | -3.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.55M | -4.38M | -5.20M | -4.25M | -3.58M |
| EBIT | -2.81M | -2.98M | -3.15M | -2.57M | -2.26M |
| EBITDA | -2.80M | -2.96M | -3.12M | -2.51M | -2.18M |
| EPS Basic | -23.87 | -23.98 | -24.08 | -17.27 | -12.44 |
| Normalized Basic EPS | -11.78 | -11.82 | -11.86 | -8.76 | -6.91 |
| EPS Diluted | -23.87 | -23.98 | -24.08 | -17.27 | -12.44 |
| Normalized Diluted EPS | -11.78 | -11.82 | -11.86 | -8.76 | -6.91 |
| Average Basic Shares Outstanding | 35.99M | 26.69M | 17.38M | 17.38M | 17.38M |
| Average Diluted Shares Outstanding | 35.99M | 26.69M | 17.38M | 17.38M | 17.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |